Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
Last trade$18.12
Day change-$1.005 (-5.26%)
Day range$18.06 – $20.03
Volume187,776
Market cap$1.02B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.02B
Price / earnings
—
Price / book
2.58×
Price / sales
—
EV / sales
—
EV / EBITDA
-7.78×
Profitability
Earnings per share
-$2.14
Return on assets
-27.39%
Return on equity
-28.78%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
17.48×
Quick ratio
17.48×
Cash ratio
3.6×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$84.77M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SPTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Revenue
$0
$0
Cost of revenue
$0
$0
Gross profit
$0
$0
Selling, general and administrative
$6.45M
$41.19M
Research and development
$23.89M
$24.62M
Total operating expenses
$30.35M
$65.81M
Operating income
-$30.35M
-$65.81M
Interest expense
$0
$0
Income before taxes
-$26.27M
-$62.35M
Income taxes
$127K
$251K
Net income
-$26.39M
-$62.6M
Net income attributable to common shareholders
-$26.39M
-$62.6M
EBITDA
-$30.32M
-$65.78M
Basic earnings per share
-$0.49
-$1.78
Diluted earnings per share
-$0.49
-$1.78
Recent news
Company coverage with links to the original publishers.
Seaport Therapeutics (SPTX) closed at $20.96 with a mean analyst price target of $37.29, suggesting 77.9% upside potential. The stock has gained 16.9% over the past four weeks. Analysts have revised earnings estimates higher, and SPTX holds a Zacks Rank #2 (Buy) rating, indicating strong near-term upside potential despite cautions about relying solely on price targets.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.